Abstract

The present disclosure provides a compound of Formula I which are naphthalene monoimide compounds, and process of preparing thereof. The compounds of the present disclosure provide reversal of cognitive decline or improvement of cognitive decline. The compounds of Formula (I) of the present disclosure synergistically modulate metal independent and dependent amyloid toxicity, scavenge reactive oxidative species (ROS), alleviate oxidative stress, emulate Nrf2 mediated stress response, mitochondrial damage, microglial activation and neuroinflammation.

IPC Classes  ?

• C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present disclosure provides a nanocomposite comprising: a. a plurality of nanoparticles having band gap in a range of 5 to 8 eV; and b. an emissive polymer, wherein the nanoparticle and the polymer are in a weight ratio in a range of 1:1 to 6:1; and the plurality of nanoparticles are dispersed in the emissive polymer. The present disclosure also provides a process of preparing the nanocomposite. The present disclosure further provides a coating composition and an article thereof.

IPC Classes  ?

• C08K 3/22 - OxidesHydroxides of metals
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C09D 5/30 - Camouflage paints
• C09D 5/32 - Radiation-absorbing paints
• C09D 5/33 - Radiation-reflecting paints
• C09D 127/04 - Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogenCoating compositions based on derivatives of such polymers not modified by chemical after-treatment containing chlorine atoms
• C09D 129/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids

Abstract

The present disclosure provides a catalyst comprising a compound comprising an ordered intermetallic of platinum and germanium having formula Pt3Ge, wherein Pt3Ge has a single crystallographic facet oriented in 202 plane. The present disclosure provides a catalyst for catalyzing hydrogen evolution reaction. The present disclosure also provides a catalyst ink, an electrode, an electrochemical cell, and methods thereof.

IPC Classes  ?

• C25B 11/089 - Alloys
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water

Abstract

The present invention relates to substituted benzophenones of structural Formula I employed as small molecule inhibitor for controlling obesity. The present invention further relates to screening of small molecule inhibitors against p300 which selectively targets histone butyrylation thereby specifically inhibiting adipogenesis further aiding to prevention of weight gain. The present invention reveals that histone butyrylation increases during adipogenesis. Hence, inhibition of histone butyrylation by a small molecule inhibitor would be a promising therapeutic strategy to control obesity. Significantly, besides inhibiting adipogenesis in cellular model, it also prevents weight gain in high fat diet based mouse model system, indicating the possible use of the scaffold for obesity control. The present invention relates to substituted benzophenones of structural Formula I employed as small molecule inhibitor for controlling obesity. The present invention further relates to screening of small molecule inhibitors against p300 which selectively targets histone butyrylation thereby specifically inhibiting adipogenesis further aiding to prevention of weight gain. The present invention reveals that histone butyrylation increases during adipogenesis. Hence, inhibition of histone butyrylation by a small molecule inhibitor would be a promising therapeutic strategy to control obesity. Significantly, besides inhibiting adipogenesis in cellular model, it also prevents weight gain in high fat diet based mouse model system, indicating the possible use of the scaffold for obesity control.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 36/38 - Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Abstract

The present disclosure discloses a compound of Formula I and the process of preparation thereof. The present disclosure discloses indirubin compounds of Formula I which are potent inducers of autophagy. The present disclosure also discloses a pharmaceutical composition comprising compound of Formula I and methods thereof.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/404 - Indoles, e.g. pindolol
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present disclosure discloses a composition comprising (2′Z, 3′E)-6-Bromoindirubin-3′-oxime or its derivative for use in treatment of neurodevelopmental and of neurodegenerative disorders. The disclosure further relates to a method for correcting the behavioural deficits in a subject with neurodevelopmental and neurodegenerative disorders comprising administering the subject with a therapeutically effective amount of (2′Z, 3′E)-6-Bromoindirubin-3′-oxime or its derivative.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61P 25/12 - AntiepilepticsAnticonvulsants for grand-mal
• A61P 25/22 - Anxiolytics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure provides a method for the treatment of epilepsy syndrome and/or seizure in a subject, by administering a therapeutically effective amount of the compound or salt thereof as disclosed herein. Embodiments herein further overcome the challenges that are generally observed with the use of existing anti- epileptic drugs, such as poor patient response, severe physical and/or psychological side effects and prevalence of drug resistance, etc. Accordingly, the present disclosure provides a compound for use in treating epilepsy syndrome and/or seizure. Also disclosed herein is a composition for the treatment of epilepsy syndrome and/or seizure.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• C07D 311/80 - DibenzopyransHydrogenated dibenzopyrans
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention describes the development of a novel, tumor epithelial cell and tumor-associated macrophage (TAM)-targeting, blood brain barrier (BBB) crossing glucose-based nanospheres (CSP). More specifically, the present invention discloses a nanoformulation and/or a composition having anticancer activity comprising of carbon nanosphere (CSP) and a sigma receptor targeting ligand (H8) in the ratio of 1:0.08 to 1:0.2, a complex prepared thereof, a process for preparation thereof and a kit for delivery of the drug molecule or the formulation or the composition to tumor site.

IPC Classes  ?

• A61K 31/4515 - Non-condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides a composition comprising: (a) 1 to 20% (w/w) indium; (b) 40 to 60% (w/w) of iron oxide; (c) 1 to 5% (w/w) of potassium; and (d) 35 to 40% (w/w) alumina. The present disclosure further provides a convenient process for 5 preparing the composition. The composition of the present disclosure is a hydrogenation catalyst. Furthermore, the present disclosure provides a process for hydrogenation of carbon dioxide to higher alcohols.

IPC Classes  ?

• B01J 23/76 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups
• B01J 23/08 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of gallium, indium or thallium
• B01J 23/04 - Alkali metals

IPC Classes  ?

• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present disclosutre provides a compound of Formula (I), its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof and a method of preparation of the same. In addition, the present disclosure provides a pharmaceutical composition comprising the compound of Formula (I) and its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions. Further, the present disclosure provides a method for prevention or treatment of neurodegenerative disease or for treatment of a condition mediated by aggregation of tau, by administering an effective amount of the compound of Formula (I), its stereoisomers, intermediates, pharmaceutically acceptable salt thereof, or the pharmaceutical composition; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions or with a clinically relevant immune modulator agent.

IPC Classes  ?

• C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to a Fluid Jet Polishing (FJP) device (200) for a workpiece (203). The FJP (200) includes a mixer (201), a nozzle (202), and an acoustic transducer (202a). The mixer (201) is adapted to mix a carrier fluid with abrasive particles. The nozzle (202) is connected with the mixer and adapted to create a jet stream of the mixture. The acoustic transducer (202a) is disposed around a radius of the nozzle (202). The acoustic transducer (202a) is adapted to generate standing acoustic waves perpendicular to a path of mixture flow within the nozzle (202) to align the abrasive particles along a centerline of the jet stream.

IPC Classes  ?

• B24C 1/08 - Methods for use of abrasive blasting for producing particular effectsUse of auxiliary equipment in connection with such methods for polishing surfaces, e.g. by making use of liquid-borne abrasives
• B24C 3/12 - Apparatus using nozzles
• B24C 7/00 - Equipment for feeding abrasive materialControlling the flowability, constitution, or other physical characteristics of abrasive blasts

Abstract

The present disclosure relates to a hemostatic porous composite comprising: a. a water- absorbing polymer matrix having a plurality of anti-microbial agent with a quaternary 5 ammonium group; and b. a plurality of inorganic material in a weight range of 0.1-30% with respect to the porous composite, wherein, the water-absorbing polymer matrix is impregnated with and is bound to the plurality of inorganic material. The present disclosure further provides a process for the preparation of the hemostatic porous composite. Furthermore, the present disclosure provides a kit, a pharmaceutical 10 composition and an article comprising the hemostatic porous composite as disclosed herein.

IPC Classes  ?

• A61L 15/16 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61L 15/18 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
• A61L 24/06 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/56 - Porous or cellular materials
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present disclosure discloses a compound of Formula (I) and its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof and a process of preparation of compounds of Formula (I). The present disclosure also discloses a method of treatment of a condition mediated by aggregation of Aβ42, tau, or α-syn. The present disclosure also discloses a compound of Formula (I) that provides reversal or improvement of cognitive decline.

IPC Classes  ?

• C07D 217/24 - Oxygen atoms
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The present disclosure provides a compound of Formula I which are naphthalene monoimide compounds, and process of preparing thereof. The compounds of the present disclosure provide reversal of cognitive decline or improvement of cognitive decline. The compounds of Formula (I) of the present disclosure synergistically modulate metal independent and dependent amyloid toxicity, scavenge reactive oxidative species (ROS), alleviate oxidative stress, emulate Nrf2 mediated stress response, mitochondrial damage, microglial activation and neuroinflammation.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide

Abstract

The present disclosure provides a compound of Formula I which are naphthalene monoimide compounds, and process of preparing thereof. The compounds of the present disclosure provide reversal of cognitive decline or improvement of cognitive decline. The compounds of Formula (I) of the present disclosure synergistically modulate metal independent and dependent amyloid toxicity, scavenge reactive oxidative species (ROS), alleviate oxidative stress, emulate Nrf2 mediated stress response, mitochondrial damage, microglial activation and neuroinflammation.

IPC Classes  ?

• C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure discloses a Pd based catalyst of the Formula I: PtxPd2-xGe, wherein 0.1≤x≤0.6, for the oxygen reduction reaction. The present disclosure provides a catalyst ink comprising a) the catalyst of Formula I: PtxPd2-xGe, wherein x is 0.1≤x≤0.6; b) a carbon black; and c) a binder. The present disclosure also provides an electrode comprising a substrate and the catalyst ink. The present disclosure further provides an electrochemical cell and a method to reduce oxygen thereof.

IPC Classes  ?

• B01J 29/00 - Catalysts comprising molecular sieves

Abstract

22322 to methanol using the catalyst.

IPC Classes  ?

• C07C 29/154 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of oxides of carbon exclusively with hydrogen or hydrogen-containing gases characterised by the catalyst used containing copper, silver, gold, or compounds thereof
• B01J 23/80 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with zinc, cadmium or mercury
• B01J 23/56 - Platinum group metals

Abstract

333Ge has a single crystallographic facet oriented in 202 plane. The present disclosure provides a catalyst for catalyzing hydrogen evolution reaction. The present disclosure also provides a catalyst ink, an electrode, an electrochemical cell, and methods thereof.

IPC Classes  ?

• B01J 37/02 - Impregnation, coating or precipitation
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,

Abstract

The present invention relates to substituted benzophenones of structural Formula I employed as small molecule inhibitor for controlling obesity. The present invention further relates to screening of small molecule inhibitors against p300 which selectively targets histone butyrylation thereby specifically inhibiting adipogenesis further aiding to prevention of weight gain. The present invention reveals that histone butyrylation increases during adipogenesis. Hence, inhibition of histone butyrylation by a small molecule inhibitor would be a promising therapeutic strategy to control obesity. Significantly, besides inhibiting adipogenesis in cellular model, it also prevents weight gain in high fat diet based mouse model system, indicating the possible use of the scaffold for obesity control.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• C07D 311/78 - Ring systems having three or more relevant rings

Abstract

The present disclosure discloses a composition comprising (2'Z, 3'E)-6-Bromoindirubin-3'-oxime or its derivative for use in treatment of neurodevelopmental and of neurodegenerative disorders. The disclosure further relates to a method for correcting the behavioural deficits in a subject with neurodevelopmental and neurodegenerative disorders comprising administering the subject with a therapeutically effective amount of (2'Z, 3'E)-6-Bromoindirubin-3'-oxime or its derivative.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• C07D 209/34 - Oxygen atoms in position 2
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure discloses a compound of Formula I and the process of preparation thereof. The present disclosure discloses indirubin compounds of Formula I which are potent inducers of autophagy. The present disclosure also discloses a pharmaceutical composition comprising compound of Formula I and methods thereof.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• C07D 209/36 - Oxygen atoms in position 3, e.g. adrenochrome

Abstract

The present disclosure describes compounds of the general Formula (I) or its stereoisomers, pharmaceutically acceptable salts, poly morphs, sols ales, hydrates, thereof. These compounds or small molecular adjuvants in combination with antibiotics are effective against resistant bacterial infections. The present disclosure also discloses a process of preparation of small-molecular adjuvants, its stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof, and to pharmaceutical compositions containing them The present disclosure describes compounds of the general Formula (I) or its stereoisomers, pharmaceutically acceptable salts, poly morphs, sols ales, hydrates, thereof. These compounds or small molecular adjuvants in combination with antibiotics are effective against resistant bacterial infections. The present disclosure also discloses a process of preparation of small-molecular adjuvants, its stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof, and to pharmaceutical compositions containing them

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/65 - Tetracyclines
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/42 - Oxazoles
• A61K 38/12 - Cyclic peptides
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents
• C07C 233/40 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
• C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
• C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin

Abstract

The present invention describes the development of a novel, tumor epithelial cell and tumor-associated macrophage (TAM)-targeting, blood brain barrier (BBB) crossing glucose-based nanospheres (CSP). More specifically, the present invention discloses a nanoformulation and/or a composition having anticancer activity comprising of carbon nanosphere (CSP) and a sigma receptor targeting ligand (H8) in the ratio of 1: 0.08 to 1: 0.2, a complex prepared thereof, a process for preparation thereof and a kit for delivery of the drug molecule or the formulation or the composition to tumor site.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/4515 - Non-condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61P 35/00 - Antineoplastic agents
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The present disclosure discloses a p-type material of Formula I: AgSb1-xCdxTe2, wherein x is in a range of 0.01-0.07. It further discloses a process of preparation of the p-type material, and the use of the p-type material as a thermoelectric material.

IPC Classes  ?

• H01L 35/16 - Selection of the material for the legs of the junction using inorganic compositions comprising tellurium or selenium or sulfur
• C01B 19/00 - SeleniumTelluriumCompounds thereof
• H01L 35/34 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof

Abstract

A catalyst including at least one group 10 metal impregnated in a mixed metal oxide is provided. The mixed metal oxide is selected from the group consisting of the oxides of In, Cu. Zn, Zr, Al, and combinations thereof. The catalyst is effective in the conversion of CO2 to value added products like methanol (CH3OH) and carbon monoxide (CO). A convenient process for preparation of the catalyst is also provided.

IPC Classes  ?

• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 23/44 - Palladium
• B01J 23/825 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with gallium, indium or thallium
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/02 - Impregnation, coating or precipitation
• C01B 32/40 - Carbon monoxide
• B01J 35/10 - Solids characterised by their surface properties or porosity
• C07C 29/154 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of oxides of carbon exclusively with hydrogen or hydrogen-containing gases characterised by the catalyst used containing copper, silver, gold, or compounds thereof

Abstract

The present disclosure discloses a compound of Formula (I) and its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof and a process of preparation of compounds of Formula (I). The present disclosure also discloses a method of treatment of a condition mediated by aggregation of Aβ42, tau, or α-syn. The present disclosure also discloses a compound of Formula (I) that provides reversal or improvement of cognitive decline.

IPC Classes  ?

• C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure discloses a compound of Formula (I) and its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof and a process of preparation of compounds of Formula (I). The present disclosure also discloses a method of treatment of a condition mediated by aggregation of Aß42, tau, or a-syn. The present disclosure also discloses a compound of Formula (I) that provides reversal or improvement of cognitive decline.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 221/14 - Aza-phenalenes, e.g. 1,8-naphthalimide

Abstract

The present disclosure relates to a composition comprising: (a) silk fibroin; and (b) ethylene glycol, wherein the ethylene glycol is selected from monoethylene glycol, tri-ethylene glycol, oligoethylene glycol, polyethylene glycol, or combinations thereof; and the silk fibroin to the ethylene glycol is in the weight ratio range of 1:1 to 1:200. The present disclosure relates to an injectable hydrogel comprising the composition and at least one therapeutic agent. The present disclosure also relates to process of preparing the composition, injectable hydrogel and methods thereof.

IPC Classes  ?

• A61K 9/52 - Sustained or differential release type
• A61L 24/10 - PolypeptidesProteins
• A61L 27/52 - Hydrogels or hydrocolloids

Abstract

The present disclosure relates to compounds of Formula I, II, III or its stereoisomers, polymorphs, solvates, hydrates, intermediates, and pharmaceutically active derivatives thereof. The present disclosure relates to a process of preparing the compounds of Formula I, II or III. The present disclosure further relates to an antimicrobial composition comprising the compounds of Formula I, II or III and method of forming an antimicrobial composition thereof. The present disclosure also relates to a method of treating a microbial infection.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• C09D 5/16 - Anti-fouling paintsUnderwater paints
• A01N 33/12 - Quaternary ammonium compounds

Abstract

The present disclosure is in the field of pharmaceutical and chemical sciences, including the synthesis of theranostic agents and processes for preparing such agents. In particular, the disclosure relates to important phenanthroline, carbazole and flavylium based cyanine group containing chemical compounds, method of preparing such molecules and compositions thereof, and the use of such molecules and compositions as a probe and diagnostic agent in the diagnosis and treatment of diseases including cancer.

IPC Classes  ?

• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• C07D 471/04 - Ortho-condensed systems
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C09B 23/04 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups one CH group, e.g. cyanines, isocyanines, pseudocyanines

Abstract

123233 is absent or dimethylformamide; b) contacting the framework I with a hydrocarbon input feed stream to obtain a purified stream and a complex of framework II. The present disclosure also provides a process for obtaining the coordination polymer porous material of framework I and a process for separation of aliphatic compound from a mixed feed stream.

IPC Classes  ?

• C07C 7/00 - Purification, separation or stabilisation of hydrocarbonsUse of additives
• C07C 7/152 - Purification, separation or stabilisation of hydrocarbonsUse of additives by treatment giving rise to a chemical modification of at least one compound by forming adducts or complexes
• C07C 7/12 - Purification, separation or stabilisation of hydrocarbonsUse of additives by adsorption, i.e. purification or separation of hydrocarbons with the aid of solids, e.g. with ion-exchangers

Abstract

p1xx2ppp-type material as a thermoelectric material.

IPC Classes  ?

• H01L 35/18 - Selection of the material for the legs of the junction using inorganic compositions comprising arsenic or antimony or bismuth
• H01L 35/34 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof

Abstract

The present disclosure discloses a recombinant vector comprising an HIV-LTR promoter comprising a nucleic acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 5 or SEQ ID NO: 6, at least one heterologous reporter gene, and at least one HIV-specific gene, wherein said HIV-specific gene encodes an HIV-specific protein under the control of the HIV-LTR promoter, and wherein the HIV-specific protein modulates activity of the HIV-LTR promoter. Further, the present disclosure also discloses a method for screening candidate molecule capable of modulating transcription of Tat gene from HIV-LTR promoter comprising a nucleic acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 5 or SEQ ID NO: 6. A method for obtaining stable cell population comprising two recombinant vectors is also described herein.

IPC Classes  ?

• C12N 15/49 - Lentiviridae, e.g. immunodeficiency viruses such as HIV, visna-maedi virus, equine infectious anaemia virus

Abstract

233OH) and carbon monoxide (CO). The present disclosure further discloses a convenient process for preparation of the catalyst.

IPC Classes  ?

• B01J 23/44 - Palladium
• C07C 29/153 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of oxides of carbon exclusively with hydrogen or hydrogen-containing gases characterised by the catalyst used
• B01J 35/02 - Solids
• B01J 35/10 - Solids characterised by their surface properties or porosity
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/18 - Reducing with gases containing free hydrogen

Abstract

The present invention discloses a method and system to evaluate the health of solar cells. The method comprises a random and non-sequential scanning of pixels of the solar cell by a focused beam of light, so as to eliminate issues arising due to spatial correlation and temporal decay profiles of adjacent pixels. Numerically controlled movable mirrors are employed to direct the focussed beam of light. The disclosed method and system can also be suited to solar cells of any configuration. Further, the system disclosed can be utilised to parallelly process multiple solar cells or solar panels and can also be integrated into a solar cell or solar panel assembly line.

IPC Classes  ?

• H02S 50/15 - Testing of PV devices, e.g. of PV modules or single PV cells using optical means, e.g. using electroluminescence

Abstract

The present disclosure relates to the field of pharmaceutical chemistry and biotechnology. The present disclosure also relates to a compound of Formula I and a process of preparation thereof. The disclosure furthermore relates to methods/use of Formula I compounds as DNA probes. Said Formula I compounds are employed for recognizing specific DNA sequences by near Infra-red (NIR)-Fluorescence Switch-on mechanism, and have related applications including but not limited to cell imaging. Also, method of treating parasitic infections by employing the present compound of Formula I is provided.

IPC Classes  ?

• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• C07D 277/10 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to a dynamic host-guest interactive system that possesses unique characteristics and finds utility in multitude of areas, specifically, in imaging and site directed drug delivery. An aspect of the present disclosure provides a dynamic host-guest interactive system including a host molecule and a guest molecule interacting with each other through non-covalent forces, wherein the host molecule is associated with any or a combination of a targeting moiety and a therapeutic agent with proviso that when the host molecule is associated with the targeting moiety, the guest molecule is associated with an imager, and when the host molecule is associated with the therapeutic agent, the guest molecule is associated with the targeting moiety, and when the host molecule is associated with a combination of the therapeutic agent and the targeting moiety, the guest molecule is associated with the imager. Another aspect provides a dynamic host-guest interactive system for site specific drug delivery of relatively less cell membrane permeable drug(s).

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present disclosure relates to a method of synthesizing shape tailored ordered intermetallic nanomaterials, PdCu3 and its application as electrocatayst in fuel cells. More particularly, the present disclosure relates to a synthesis of ordered PdCu3 nanomaterial starting from a spherical nanocrystal with crystallographically exposed (111) plane to a cubic nanocrystal with (100) plane, and its excellent efficiency as both cathode and anode material, surpassing the activity and stability of the state-of-the-art Pt/C electrocatalyst. The present disclosusre further relates to the unique, cost-effective way of synthesizing ordered Pd based nanocrystal in different shapes with different exposed crystallographic planes for catalysis. The present disclosure also relates to fuel cell device fabrication and applications of said nanomaterial as bi-functional electrode material (active as both anodic and cathodic electrode material).

IPC Classes  ?

• H01M 4/92 - Metals of platinum group
• H01M 8/1018 - Polymeric electrolyte materials

Abstract

The present invention relates to a catalyst for a polymer electrolyte fuel cell comprising a metal-based chalcogenide comprising a transition metal and/or a noble metal and a chalcogen. The present invention also provides a one-pot method for synthesizing metal-based chalcogenide nanoparticle comprising: (i) mixing one or more metal acetylacetonate or acetate based precursor with a chalcogen precursor in a solvent to obtain a reaction solution; (ii) adding a reagent to the reaction solution; (iii) heating the reaction solution of step (ii) to obtain a reaction product; and (iv) washing the reaction product and drying to obtain a metal-based chalcogenide nanoparticle. The present invention relates to a synthesis of highly stable and durable nanomaterials with selenium rich surface. The catalyst outperforms the present state-of-the-art material Pt/C and Pd/C in terms of stability and durability.

IPC Classes  ?

• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material
• H01M 4/92 - Metals of platinum group
• H01M 8/1018 - Polymeric electrolyte materials

Abstract

The present disclosure relates to the field of synthetic pharmaceutical chemistry and biology. The disclosure provides a compound of Formula I and a process of preparation thereof. The disclosure further relates to methods and use of Formula I compounds as stimuli-responsive probes. Said Formula I compounds are employed for detecting and quantifying reactive oxygen species (ROS), and have related applications including but not limited fluorescence spectroscopy, diagnostics, treatment, imaging and biomedical applications.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• A61K 31/69 - Boron compounds
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present disclosure relates to a polymer network comprising a compound of Formula I cross-linked to a compound selected from the group consisting of a compound of Formula II; hyaluronate aldehyde, alginate aldehyde, dextran aldehyde, starch aldehyde, and chitosan aldehyde. It also relates to a process of preparing the polymer network. The present disclosure further relates to compositions comprising the polymer network and methods of preventing conditions and diseases that are caused by micro-organism. The present disclosure still further relates to a biocompatible antimicrobial hydrogel, a process for preparing the hydrogel, and methods of using the same, including a variety of tissue-related applications in which rapid adhesion to the tissue and gel formation is desired, as well as local delivery of pharmaceutical drugs to a site of application.

IPC Classes  ?

• C08B 31/00 - Preparation of chemical derivatives of starch
• C08B 37/02 - DextranDerivatives thereof
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof

Abstract

The present disclosure relates to the field of biomaterials, tissue engineering and regenerative medicine. Particularly, the present disclosure relates to biomaterial composite and preparation of various scaffold formats using the composite. The disclosure provides for preparation of biomaterial composite comprising silk fibroin and melanin, preparation of scaffolds with the biomaterial composite and its applications in tissue engineering, electrotherapy applications and regenerative medicine. In some embodiments, the silk fibroin is a peptide modified silk fibroin. The biomaterial composite of the present disclosure exhibits various advantages including but not limiting to enhanced antioxidant property, superior electroactive properties, improved myogenic cell differentiation, better cell growth and regeneration, and enhanced cell adhesion property.

IPC Classes  ?

• A61L 27/22 - Polypeptides or derivatives thereof

Abstract

The present disclosure relates to method of modulating autophagy by modulators of autophagy, wherein the autophagy includes but is not limited to macroautophagy, chaperone mediated autophagy and microautophagy. The present disclosure further relates to modulators of autophagy for increasing or decreasing the autophagic flux. The disclosure also relates to modulator per se in modulating autophagy including but not limiting to macroautophagy, chaperon mediated autophagy and microautophagy.

IPC Classes  ?

• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present disclosure relates to compounds which function as small molecule fluorescent probes which aid in recognition of specific sequences in DNA and detection of Aβ aggregates. Probes/dyes of the instant disclosure are specific to AT-rich sequences of DNA and Aβ aggregates. These small organic dyes/probes are capable of exhibiting switch-on fluorescence and play an important role in fluorescence spectroscopy, diagnostics, imaging and biomedical applications.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 421/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups
• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to the field of synthetic pharmaceutical chemistry and biology. The disclosure provides a compound of Formula I and a process of preparation thereof. The disclosure further relates to methods and use of Formula I compounds as stimuli-responsive probes. Said Formula I compounds are employed for detecting and quantifying reactive oxygen species (ROS), and have related applications including but not limited fluorescence spectroscopy, diagnostics, treatment, imaging and biomedical applications.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• A61K 31/69 - Boron compounds

Abstract

The present disclosure relates to the field of pharmaceutical chemistry and biotechnology. The present disclosure also relates to a compound of Formula I and a process of preparation thereof. The disclosure furthermore relates to methods/use of Formula I compounds as DNA probes. Said Formula I compounds are employed for recognizing specific DNA sequences by near Infra-red (NIR)-Fluorescence Switch-on mechanism, and have related applications including but not limited to cell imaging. Also, method of treating parasitic infections by employing the present compound of Formula I is provided.

IPC Classes  ?

• C07D 277/10 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• A61K 31/425 - Thiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to an electron deficient boron based conjugated microporous polymers (BCMP) comprising a boron appended triarylborane porous conjugated microporous polymers solid adsorbents, featuring triarylborane having Lewis acidic boron centers separated by organic linkers as integral part of polymeric network. The present invention also relates to a process for the preparation of electron deficient boron based conjugated microporous polymers. The present invention also provides a process for detection of fluoride in water or in substance which contains fluoride by using BCMP.

IPC Classes  ?

• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators

Abstract

The present disclosure provides compositions comprising colloidal matter in solvent, employed for crackle formation when exposed to surface of a substrate. The said compositions crackle spontaneously without any external stimuli when exposed to the substrate surface as a film. The present disclosure also relates to substrates having a film by exposure to said composition and a method of preparing said substrate. The present disclosure also relates to patterned substrates fabricated with material or energy inputs deposited in template formed by crackling of the film and a method of preparing said patterned substrate and a kit for obtaining such substrates. The present disclosure also relates to using the said substrates for various applications specifically in the field of electronics or optoelectronics.

IPC Classes  ?

• B32B 5/16 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer formed of particles, e.g. chips, chopped fibres, powder
• C09D 5/28 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes for wrinkle, crackle, orange-peel, or similar decorative effects
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• B05D 1/00 - Processes for applying liquids or other fluent materials
• B05D 1/02 - Processes for applying liquids or other fluent materials performed by spraying
• B05D 3/06 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to radiation
• H01B 1/02 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of metals or alloys
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present disclosure relates to compounds which function as small molecule fluorescent probes which aid in recognition of specific sequences in DNA and detection of Αβ aggregates. Probes/dyes of the instant disclosure are specific to AT-rich sequences of DNA and Αβ aggregates. These small organic dyes/probes are capable of exhibiting switch-on fluorescence and play an important role in fluorescence spectroscopy, diagnostics, imaging and biomedical applications.

IPC Classes  ?

• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 421/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Abstract

The present disclosure relates to polyamine conjugates, its isomers, prodrugs and pharmaceutically acceptable salts thereof. The present disclosure also relates to process of preparation of polyamine conjugates, its stereoisomers, prodrugs, pharmaceutically acceptable salts thereof,and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases mediated by microbes.

IPC Classes  ?

• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals

Abstract

The present invention is in relation to a composition including nanosphere and histone acetyltransferase (HAT) activator. The nanosphere is carbon nanosphere (CSP) which is intrinsically fluorescent and the HAT activator is N-(4-Chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide. The N-(4-Chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide is covalently conjugated with the carbon nanosphere. The present invention further relates to a process for obtaining a composition including carbon nanosphere and Histone acetyltransferase (HAT) activator [N-(4-Chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide]. The composition is capable of crossing blood brain barrier and inducing histone acetylation in brain. Further, the composition is capable of increasing neurogenesis, as well as improving long-term memory formation. The composition manages pathological conditions to a subject in need thereof, such as aging-related, neurodegenerative diseases (Alzheimer's in particular), neurological disorders, depression or other kinds of diseases in which increased HAT activity, neurogenesis and/or memory improvement would benefit.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present disclosure relates to a method of synthesizing intermetallic nanoparticle with a crystal structure of NiAs type, wherein said method is a modified polyol method. The disclosure particularly discloses NiSb, CoSb, NiPb PdSb and other intermetallic compounds having a similar structure type, synthesized by the above said method and also describes the catalytic activity of the said intermetallic nanoparticle. The modified polyol method of the instant disclosure is rapid and cost effective when compared to the conventional methods employed to synthesize the intermetallic nanoparticles.

IPC Classes  ?

• C22C 13/00 - Alloys based on tin

Abstract

The present disclosure relates to a process for bromination of arylene dianhydrides, particularly1,4,5,8-naphthalenetetracarboxylic dianhydride (NDA) using 5,5-dimethyl-1,3- dibromohydantoin (DBH) or tribromoisocyanuric acid (TBCA) as brominating agent. The disclosure further relates to condensation of the brominated dianhydrides with amines to yield corresponding imides, particularly naphthalene diimides (NDI) which are versatile precursors for the synthesis of core functionalized naphthalene diimides. The present disclosure further relates to the use of DBH or TBCA as brominating agents for brominating arylene dianhydride, particularly naphthalene tetracarboxylic dianhydride.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C07D 471/06 - Peri-condensed systems
• C07D 233/82 - Halogen atoms

Abstract

The present disclosure relates to semiconductor nanomaterials, preferably quantum dots (QDs), methods to obtain said nanomaterials and applications thereof. More particularly, the present disclosure relates to Cd-based-chalcogenide/CdS core-shell nanomaterial starting from a defective core nanocrystal and thick shell structure (greater than 3 nm thickness) with a high quantum yield (greater than 80%), and methods of obtaining the said nanomaterial. The present disclosure further relates to defective/defect-free Cd-based-chalcogenide core nanocrystal and method for synthesizing the defective/defect-free core. The present disclosure also relates to devices and applications of said nanomaterial and the defective/defect-free Cd-based-chalcogenide core.

IPC Classes  ?

• C09K 11/88 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing selenium, tellurium or unspecified chalcogen elements

Abstract

The present disclosure provides compositions comprising colloidal matter in solvent, employed for crackle formation when exposed to surface of a substrate. The said compositions crackle spontaneously without any external stimuli when exposed to the substrate surface as a film. The present disclosure also relates to substrates having a film by exposure to said composition and a method of preparing said substrate. The present disclosure also relates to patterned substrates fabricated with material or energy inputs deposited in template formed by crackling of the film and a method of preparing said patterned substrate and a kit for obtaining such substrates. The present disclosure also relates to using the said substrates for various applications specifically in the field of electronics or optoelectronics.

IPC Classes  ?

• B32B 3/26 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids

Abstract

The present disclosure relates to the field of medicinal chemistry and more particularly to the development of antimicrobial compounds. The disclosure relates to the synthesis and characterization of compounds comprising aromatic radical or an aliphatic radical, an alkyl amine and amino acid moiety wherein said compounds exhibit antimicrobial activity against various drug-sensitive and drug-resistant pathogenic 10 microorganisms.

IPC Classes  ?

• A61K 38/05 - Dipeptides

Abstract

The disclosure relates to a method of oxidation of an aliphatic C-H bond in an organic compound using CdO2 or ZnO2 nanoparticles as oxidizing agents. The instant disclosure relates to a method of oxidizing toluene using metal peroxide nanoparticles such as CdO2, ZnO2 as oxidizing agents to obtain oxidized products predominantly comprising benzaldehyde.

IPC Classes  ?

• C07C 51/16 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation

Abstract

The present disclosure relates to a method of performing an assay to monitor the overall autophagic flux within a host cell particularly, macro autophagy, pexophagy and other autophagic pathways. The present disclosure also relates to a vector or expression construct and host cell suitable for being employed in the assay to monitor autophagy and a kit thereof.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• G01N 21/76 - ChemiluminescenceBioluminescence
• G01N 33/554 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
• G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction

Abstract

The present disclosure relates to monoclonal antibodies against NPM1 and acetylated NPM1 and a method for generating the same. Particularly, the present disclosure relates to monoclonal antibodies against acetylated NPM1 which are acetylation site specific. The present disclosure further relates to a kit comprising said monoclonal antibodies for the detection and treatment of oral cancer.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present disclosure relates to the development of antibacterial compounds and their nanoparticle compositions. Methods of making the compounds and their nanoparticle compositions, their use as medicament for the treatment of bacterial infection and also for suppressing potentially harmful inflammation are disclosed.

IPC Classes  ?

• C08F 222/40 - Imides, e.g. cyclic imides
• C08F 210/10 - Isobutene
• C08F 8/32 - Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
• C08F 8/48 - IsomerisationCyclisation
• C08F 8/02 - Alkylation
• C08F 8/44 - Preparation of metal salts or ammonium salts
• C08F 8/12 - Hydrolysis
• C08J 3/03 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
• C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
• A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
• A61K 9/107 - Emulsions
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C08L 23/22 - Copolymers of isobuteneButyl rubberHomopolymers or copolymers of other iso-olefins
• C08L 35/00 - Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereofCompositions of derivatives of such polymers
• C09D 123/22 - Copolymers of isobuteneButyl rubber

Abstract

The present disclosure is in relation to nanotechnology/nanobiotechnology, in particular to nano, meso and micro structures of Naphthalene diimide derivatives. The disclosure provides a method for supramolecular self-assembling of Naphthalene diimide derivatives, its characteristics and its applications. The present disclosure also relates to self assembled nano, meso or micro-structures of the Naphthalene diimide derivatives.

IPC Classes  ?

• H01B 1/00 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• C07K 5/00 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof
• H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances
• C07D 471/06 - Peri-condensed systems
• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp

Abstract

The present disclosure is in relation to a composition comprising nanosphere and histone acetyltransferase (HAT) activator. The disclosed nanosphere is carbon nanosphere (CSP) which is intrinsically fluorescent and the HAT activator is N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide [COMPOUND 1]. The said N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide is covalently conjugated with the carbon nanosphere. The present disclosure further relates to a process for obtaining a composition comprising carbon nanosphere and Histone acetyltransferase (HAT) activator [N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide]. The composition is capable of crossing blood brain barrier and inducing histone acetylation in brain. Further, the composition is capable of increasing neurogenesis, as well as improving long-term memory formation. The said composition thus provides for managing pathological conditions to a subject in need thereof, such as aging- related, neurodegenerative diseases (Alzheimer's in particular), neurological disorders, depression or other kinds of diseases in which increased HAT activity, neurogenesis and/or memory improvement would benefit.

IPC Classes  ?

• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 49/00 - Preparations for testing in vivo
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure relates to photo voltaic cells that are more efficient and stable than conventional photo voltaic cells. The present disclosure also relates to process for preparing such photo voltaic cells, which is inherently low-cost, less complex and results in a stable device.

IPC Classes  ?

• H01L 51/44 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation - Details of devices
• H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation

Abstract

Methods and devices for preparing microscale polymer relief structures from a thin polymer layer on an absorbing substrate are described. The described methods are ultrafast (about 8 nanoseconds) and allow formation of patterned microstructures having complex morphologies and narrow line widths that are an order of magnitude smaller than the masks used in the methods.

IPC Classes  ?

• B05D 3/06 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to radiation
• B05D 3/00 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials

Abstract

Embodiments of the present disclosure relate to a system and method to detect hydrogen leakage. The system uses a fluid sensing apparatus (104), a light source (120) and and photo detector (122). The nano-crystallised palladium gratings (118) are used as sensors which expand sensitively upon exposure to the hydrogen ( H2). In an embodiment, the hydrogen sensing is based on monitoring the changes in the diffraction efficiency (DE) which is defined as the ratio of the first and the zeroth order diffracted beam intensities. The diffraction efficiency undergoes large and sudden changes as the nano-crystalline Pd grating becomes highly disordered due to PdHx formation. An embodiment of the present disclosure also relates to producing nanocrystalline Pd diffraction gratings along with the design and fabrication aspects of an indigenously built optical diffraction cell for H2sensing.

IPC Classes  ?

• G01N 21/47 - Scattering, i.e. diffuse reflection
• G01N 21/85 - Investigating moving fluids or granular solids
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 3/38 - Investigating strength properties of solid materials by application of mechanical stress by applying repeated or pulsating forces generated by electromagnetic means
• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor

Abstract

The present invention relates to compounds that are cationic vancomycin analogues and their compositions. Method of making the compounds and their use as medicament for the treatment of bacterial infection are also disclosed.

IPC Classes  ?

• C07K 9/00 - Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequenceDerivatives thereof
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof

Abstract

The present disclosure relates to a polymer comprising repeating tetra phenyl pyrene monomer unit(s). The disclosure further relates to method of arriving at said polymer and methods of detecting, removing and recovering compounds by employing said polymer. Further, use of the polymer for the detection, removal and recovery of various compounds such as volatile organic compound, polycyclic aromatic hydrocarbon and aromatic pollutant is also disclosed.

IPC Classes  ?

• C08G 61/10 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aromatic carbon atoms, e.g. polyphenylenes
• B01D 53/00 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols

Abstract

The present technology provides a color-sensing device that includes an electrically-conductive substrate and a bulk heterojunction (BHJ) polymer layer formed on the substrate. The color-sensing device is configured to detect a first color of two colors and produce a first electrical signal that includes a first current response indicating detection of the first color. The color-sensing device is further configured to detect a second color of the two colors and produce a second electrical signal that includes a second current response indicating detection of the second color.

IPC Classes  ?

• G01J 3/46 - Measurement of colourColour measuring devices, e.g. colorimeters
• H01L 27/30 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including components using organic materials as the active part, or using a combination of organic materials with other materials as the active part with components specially adapted for either the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
• H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation

Abstract

Implementations and techniques for manufacturing strain sensitive sensors and/or strain resistant conduits from a metal and carbon matrix are generally disclosed.

IPC Classes  ?

• G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges

Abstract

The present disclosure is in relation to nanotechnology/nanobiotechnology, in particular to nano, meso and micro structures of Naphthalene diimide derivatives. The disclosure provides a method for supramolecular self-assembling of Naphthalene diimide derivatives, its characteristics and its applications. The present disclosure also relates to self assembled nano, meso or microstructures of the Naphthalene diimide derivatives.

IPC Classes  ?

• C07D 221/18 - Ring systems of four or more rings
• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp

Abstract

The disclosure relates to a method of identification of antiviral molecules that help in efficient viral control and thereby aid in disease management. In particular, the disclosure relates to identification of anti-Tat molecules and hence is directed towards antiviral drug development. The disclosure also relates to Tat-inducible GFP- anti RFP shRNA vector, vector combinations, recombinant cell having instant vectors, methods and kits thereof.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present technology provides an organic based artificial retina device that includes a substrate and an array of micro-electrodes formed on the substrate. The illustrative artificial retina device further includes a photoconducting polymer blend deposited on the array of micro-electrodes. The photoconducting polymer blend is configured to produce a photoelectric signal in response to receiving light.

IPC Classes  ?

• A61F 9/08 - Devices or methods enabling eye-patients to replace direct visual perception by another kind of perception
• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation

Abstract

The present disclosure relates to phosphorylation of NPM1 by Aurora kinases A and B at a single residue, serine 125 during mitosis. In order to detect the phosphorylated-S125- NPM1 in the cells, highly specific antibodies were generated against it. Hence the present disclosure also relates to highly specific antibodies to detect Aurora kinases A and B phosphorylation at Ser125-NPM1 and its uses thereof.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The disclosure relates to preparation and self-assembly of aromatic cyclic dipeptide into one and two dimensional nano, meso and micro structures. The said structures of cyclic dipeptide can be electrospinned into threads, fabrics, suture, bandage materials. They are also useful in cell culturing, tissue culturing, drug delivery system, as composite materials, as inhibitors of fibrillization and in Biomedical research such as neurological regeneration and organ replacement studies.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 5/12 - Cyclic peptides

Abstract

The present disclosure relates to a method for inhibiting histone acetyltransferases by derivative of curcumin, particularly CTK7A. The present disclosure also relates to identification of induction of autoacetylation of p300 and its inhibition by CTK7A. The disclosure also relates to induction of NPM1 and GAPDH overexpression and corresponding hyperacetylation of histone and methods thereof.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61K 31/415 - 1,2-Diazoles
• A61K 38/45 - Transferases (2)
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The disclosure relates to Aeronautics, more particularly relating to wing planforms that reduce wing drag substantially in aircraft driven by propellers or other rotors in tractor configuration. An aircraft comprising a wing and propeller system (1), said system comprising wing planform (2) characterized into wing chord regions (3) behind each propeller/rotor (5) whose length is relatively varied with respect to length of wing chord regions (4) at outboard of the propeller/rotor (5) towards wing tip and/or at inboard of the propeller (5) towards fuselage, and plurality of propellers (5) fixed ahead of wing leading edge such that induced drag is reduced by exploiting the velocity field generated by the slipstream of the propeller (5). Also, provides for a method of optimizing wing and propeller system and a method reducing induced drag, among other possible parameters of interest.

IPC Classes  ?

• B64F 5/00 - Designing, manufacturing, assembling, cleaning, maintaining or repairing aircraft, not otherwise provided forHandling, transporting, testing or inspecting aircraft components, not otherwise provided for
• G06F 17/10 - Complex mathematical operations
• B64C 3/10 - Shape of wings
• G06Q 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

The present invention relates to a SERS active paper substrate comprising in- situ synthesized nanoparticles. The paper substrate is used for obtaining Raman spectra of an analyte. The invention further relates to a process for obtaining SERS active paper substrate comprising in-situ synthesized nanoparticles, as well as a method to determine Raman Spectra of an analyte with the help of this SERS active paper substrate.

IPC Classes  ?

• D21H 25/06 - Physical treatment, e.g. heating or irradiating of impregnated or coated paper
• G01J 3/44 - Raman spectrometryScattering spectrometry
• G01N 21/65 - Raman scattering

Abstract

The present invention relates to identification of centromeric sequences of Candida dubliniensis and localization of CdCse4p centromeric histone to the identified region. Also the present invention relates to distinguishing Candida dubliniensis from other members of genus Candida.

IPC Classes  ?

• C12N 1/14 - Fungi Culture media therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides solution to the problem involved in preparation of metal nanosponges using templates and polymers. The instant invention is successful in providing a simple, template free single step process for the preparation of metal nanosponges having porous low density and high surface area. These metal nanosponges were found to be good self-supported substrates for surface-enhanced Raman spectroscopy (SERS) and have shown significant anti-bacterial activity.

IPC Classes  ?

• B82B 1/00 - Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Abstract

The present invention relates to non toxic, immunogenic viral Tat DNA sequences comprising wherein the Tat Sequence is rendered non toxic and immunogenic by insertion of T-Helper Epitope into the Cysteine-rich domain, or Basic domain or Core domain of said Tat DNA sequence, optionally along with insertion of a synthetic Intron between C-terminal region and Exon II region of the Tat DNA Sequence. The present invention also relates to elongation factor promoter constructs and process thereof. Also the present invention relates to a process of obtaining the non toxic and immunogenic Tat DNA sequence and vaccine and a method thereof.

IPC Classes  ?

• C12N 15/48 - Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present invention relates to nanoparticle composition comprising cellulose nanofibers embedded with nanosized material. More particularly the present invention relates to cellulose nanofibers embedded with silver or iron oxide embedded silver. In addition the present invention is also related to the preparation of the cellulose nanofibers embedded with nanosized material. The nanoparticle composition is antibacterial in nature and can be utilized in various antibacterial applications.

IPC Classes  ?

• C08L 1/02 - CelluloseModified cellulose
• D01F 2/00 - Monocomponent artificial filaments or the like of cellulose or cellulose derivativesManufacture thereof
• C08K 3/08 - Metals
• A01N 25/26 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
• D21H 21/36 - Biocidal agents, e.g. fungicidal, bactericidal or insecticidal agents

Abstract

The present invention provides solution to the problem involved in delivery of active molecules to nucleus. More particularly, the invention provides intrinsically fluorescent and inherently surface functionalized carbon nanospheres which are non-toxic. Also, these carbon nanospheres [CSP] were adsorbed with CTPB [CSP-CTPB] and the adsorbed CSP-CTPB are permeable to cells with nuclear targeting ability. In addition, the present invention provides a composition, a process to prepare the composition comprising CSP with adsorbed active/ therapeutic molecules. Further, the instant invention provides a method for delivering active molecules inside a cell nucleus.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The present invention relates to a high sensitivity assay for molecular typing of a biological sample using surface-enhanced Raman scattering (SERS) including resonance scattering (SERRS); capture probes for capturing nucleic acid; a detector probe to detect captured nucleic acid; a kit for molecular typing of biological sample using surface-enhanced Raman scattering (SERS) including resonance scattering (SERRS); and lastly a method of manufacturing said kit.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

The present invention relates to compounds of structural formula (I) as site-specific inhibitor of histone methyltransferase, where R1 and R1 is -OCH or -OH, R2 and R2 is -OH or -OAc; a process of isolating compound of structural formula (Ia), where R1 and R1 is -OCH, R2 and R2 is -OH; a process of preparation of compound of structural formula (Ib), where R1 and R1 is -OCH, R2 and R2 is -OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is -OH, R2 and R2 is -OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and /or disease conditions in a subject in need thereof.

IPC Classes  ?

• C07C 65/105 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
• C07C 51/42 - SeparationPurificationStabilisationUse of additives
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid

Abstract

The present invention is in relation to the derivatives of 4,6-disubstituted 1,2,4-triazolo-1, 3, 4-thiadiazole and a process to synthesize the said derivatives. Also, the present invention was able to establish the activity of the instant derivatives against anti-cancerous activity specific to cervical and oral cancer.

IPC Classes  ?

• C07D 513/04 - Ortho-condensed systems
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/433 - Thiadiazoles
• A61K 31/4196 - 1,2,4-Triazoles